James E. Levine
CIK 1463151 · Chief Financial Officer · last filed 2026-06-23
James E. Levine is a Chief Financial Officer who has filed 29 SEC Form 4 insider transactions across 4 companies since 2009. The most recent filing, for KZIA, was dated Jun 23, 2026. Across all open-market trades the lifetime net is +$757.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $100.8K across reported positions. 2 SEC filings were submitted jointly with NOVOGEN LTD.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRDF price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
8TH FLOOR
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KZIA | Chief Financial Officer | — | $7.87 | — | $0 | 1 | 2026-06-23 |
| CRDF | Chief Financial Officer | 125,316 | $0.80 | $100.8K | $277.4K | 8 | 2025-03-13 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Chief Financial Officer | 5,990 | $221.38 | $1.33M | $215.2K | 7 | 2021-03-19 |
| VERENIUM CORP (VRNM) Delisted | President & CEO | 109,166 | — | — | $265.2K | 12 | 2013-08-02 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-23 | KZIA | Grant (A) | — | $0 | EDGAR |
| 2025-03-13 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2024-12-18 | CRDF | Buy (P) | +7,716 | $36.7K | EDGAR |
| 2024-03-07 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2023-03-16 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2022-09-19 | CRDF | Buy (P) | +30,000 | $46.7K | EDGAR |
| 2022-03-10 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2021-09-13 | CRDF | Buy (P) | +30,000 | $194.0K | EDGAR |
| 2021-07-12 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2021-03-19 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.